CSL Limited CSL Limited

CSL Limited

CSL

주식 순위 #361
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
주가
$138.58
시가총액
$66.50B
변동 (1일)
0.72%
변동 (1년)
-2.29%
국가
AU
거래 CSL Limited (CSL)

카테고리

Healthcare
CSL Limited (CSL)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 4.21
CSL Limited의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 4.21입니다. 2024년 말 기준 P/B 비율은 5.43였습니다.
CSL Limited의 P/B 비율 기록 (2000 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 4.21 6.80%
2025 3.94 -27.38%
2024 5.43 44.67%
2023 3.75 -8.59%
2022 4.11 -64.62%
2021 11.60 -41.84%
2020 19.95 52.81%
2019 13.06 -17.71%
2018 15.87 -20.12%
2017 19.87 32.34%
2016 15.01 -0.22%
2015 15.04 47.75%
2014 10.18 1.25%
2013 10.06 70.32%
2012 5.91 28.39%
2011 4.60 -10.55%
2010 5.14 17.45%
2009 4.38 -40.16%
2008 7.31 -12.44%
2007 8.35 25.21%
2006 6.67 58.64%
2005 4.21 53.56%
2004 2.74 23.37%
2003 2.22 -67.73%
2002 6.88 -56.70%
2001 15.89 71.69%
2000 9.25 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.251 48.55%
US
13.2547 214.99%
US
- -
CH
6.1824 46.92%
NL
3.2932 -21.74%
BE